The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma

Takaki, 2008, Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development, Curr Opin Cell Biol, 20, 650, 10.1016/j.ceb.2008.10.005 Ikezoe, 2009, A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies, Leukemia, 23, 1564, 10.1038/leu.2009.94 Renner, 2009, Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells, Blood, 114, 659, 10.1182/blood-2008-12-195867 Steegmaier, 2007, BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo, Curr Biol, 17, 316, 10.1016/j.cub.2006.12.037 Ramasamy K, Khatun H, Macpherson L, Mufti GJ, Schey S, Calle Y. Direct effect on the stroma by the conventional anti-multiple myeloma drug dexamethasone results in resistance of multiple myeloma plasma cells against therapy. Sensitisation to dexamethasone by the kinase inhibitor dasatinib. American Society of Haematology Annual Scientific Meeting, Abstract 193, December 2010. Stewart, 2009, Substrate-induced phenotypical change of monocytes/macrophages into myofibroblast-like cells: a new insight into the mechanism of in-stent restenosis, J Biomed Mater Res A, 90, 465, 10.1002/jbm.a.32100 Tategu, 2008, Transcriptional regulation of human polo-like kinases and early mitotic inhibitor, J Genet Genom, 35, 215, 10.1016/S1673-8527(08)60030-2 Dezorella, 2009, Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6, Exp Cell Res, 315, 1904, 10.1016/j.yexcr.2009.03.016 Poder, 2009, Bone marrow microenvironment and the identification of new targets for myeloma therapy, Leukemia, 23, 10, 10.1038/leu.2008.259 Strebhardt, 2010, Multifaceted polo-like kinases drug targets and antitargets for cancer therapy, Nat Rev Drug Discov, 9, 643, 10.1038/nrd3184 Schöffski, 2009, Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology, Oncologist, 14, 559, 10.1634/theoncologist.2009-0010 Winkless, 2005, Differential regulation of polo-like kinases 1,2,3 and 4 gene expression in mammalian cells and tissues, Oncogene, 24, 260, 10.1038/sj.onc.1208219 Zimmerman, 2007, Polo-like kinase 3 is required for entry into S phase, Proc Natl Acad Sci U S A, 104, 1847, 10.1073/pnas.0610856104 Dai, 2002, Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors, Int J Oncol, 20, 121 Habedanck, 2005, The Polo kinase Plk4 functions in centriole duplication, Nat Cell Biol, 7, 1140, 10.1038/ncb1320 Drewinko, 1981, The growth fraction of human myeloma cells, Blood, 57, 333, 10.1182/blood.V57.2.333.333 Sebastian, 2010, The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial, J Thorac Oncol, 5, 1060, 10.1097/JTO.0b013e3181d95dd4 Lens, 2010, Shared and separate functions of polo-like kinases and aurora kinases in cancer, Nat Rev Cancer, 10, 825, 10.1038/nrc2964 Fulda, 2009, Caspase-8 in cancer biology and therapy, Cancer Lett, 281, 128, 10.1016/j.canlet.2008.11.023 Basak, 2009, Multiple myeloma bone marrow niche, Curr Pharm Biotechnol, 10, 345, 10.2174/138920109787847493 Meads, 2008, The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance, Clin Cancer Res, 14, 2519, 10.1158/1078-0432.CCR-07-2223 Zhang, 1989, Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma, Blood, 74, 11, 10.1182/blood.V74.1.11.11 Negri, 2009, In vitro anti-myeloma activity of the aurora kinase inhibitor VE-465, Br J Haematol, 147, 672, 10.1111/j.1365-2141.2009.07891.x Macůrek, 2008, Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery, Nature, 455, 119, 10.1038/nature07185 Shi, 2007, Targeting aurora kinases as therapy in multiple myeloma, Blood, 109, 3915, 10.1182/blood-2006-07-037671 Chng, 2008, The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition, Blood, 111, 1603, 10.1182/blood-2007-06-097774 Evans, 2008, The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma, Br J Haematol, 140, 295, 10.1111/j.1365-2141.2007.06913.x Hose, 2009, Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma, Blood, 113, 4331, 10.1182/blood-2008-09-178350 Evans, 2008, Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells, Leuk Lymphoma, 49, 559, 10.1080/10428190701824544 Wang, 2010, Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma, Br J Haematol, 150, 313, 10.1111/j.1365-2141.2010.08248.x Görgün, 2010, A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma, Blood, 115, 5202, 10.1182/blood-2009-12-259523 Chopra, 2010, Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics, Exp Opin Invest Drugs, 19, 27, 10.1517/13543780903483191